Ciprofloxacin: Microbiology — Pharmacokinetics — Clinical Experience

Front Matter....Pages I-VII
Front Matter....Pages 1-1
A Laboratory Assessment of Ciprofloxacin and Comparable Antimicrobial Agents....Pages 3-7
Comparative in Vitro Activity of Five Quinoline Derivatives and Five Other Antimicrobial Agents Used in Oral Therapy....Pages 8-13
The In Vitro and In Vivo Activity of Ciprofloxacin....Pages 14-18
The Activity of Ciprofloxacin and Other 4-Quinolones Against Chlamydia trachomatis and Mycoplasmas In Vitro....Pages 19-21
Mutational Resistance to 4-Quinolone Antibacterial Agents....Pages 22-25
Antibacterial Activity of Ciprofloxacin in Conventional Tests and in a Model of Bacterial Cystitis....Pages 26-29
Comparison of the in Vitro Activity of Ciprofloxacin (Bay o 9867) and Norfloxacin Against Gastrointestinal Tract Pathogens....Pages 30-30
In Vitro Activity of Ciprofloxacin, Azthreonam and Ceftazidime Against Serratia marcescens and Pseudomonas aeruginosa ....Pages 31-32
In Vitro Activity of Ciprofloxacin Against Bacteroides , Haemophilus influenzae and Branhamella catarrhalis ....Pages 33-34
In Vitro Activity of Ciprofloxacin Against Brucella melitensis ....Pages 34-34
In Vitro Activity of Ciprofloxacin Against Clinical Isolates of Chlamydia trachomatis ....Pages 35-35
Susceptibility of Legionella spp. to Quinolone Derivatives and Related Organic Acids....Pages 36-36
In Vitro Activity of Ciprofloxacin and Norfloxacin Against Gardnerella vaginalis ....Pages 37-37
In Vitro Activity of Ciprofloxacin Against Group JK Corynebacteria....Pages 38-38
Front Matter....Pages 39-39
Pharmacokinetics of Ciprofloxacin in Healthy Volunteers after Oral and Intravenous Administration....Pages 41-48
Pharmacokinetics of Ciprofloxacin after Intravenous and Increasing Oral Doses....Pages 49-54
Single and Multiple Dose Pharmacokinetics of Ciprofloxacin....Pages 55-58
Penetration of Ciprofloxacin into Bronchial Secretions....Pages 59-62
Effect of Oral Ciprofloxacin on the Faecal Flora of Healthy Volunteers....Pages 63-67
Diffusion of Ciprofloxacin into Prostatic Fluid....Pages 68-70
Front Matter....Pages 39-39
Dose- and Sex-Independent Disposition of Ciprofloxacin....Pages 71-74
Penetration of Ciprofloxacin into Cerebrospinal Fluid....Pages 75-76
Penetration of Ciprofloxacin into Female Pelvic Tissues....Pages 76-78
Intraperitoneal Penetration of Ciprofloxacin....Pages 78-79
Concentrations of Ciprofloxacin in Serum and Prostatic Tissue in Patients Undergoing Transurethral Resection....Pages 80-81
Penetration of Ciprofloxacin into Kidney, Fat, Muscle and Skin Tissue....Pages 81-82
Front Matter....Pages 83-83
Overview of Clinical Experience with Ciprofloxacin....Pages 85-90
Clinical Experience with Ciprofloxacin in the USA....Pages 91-96
Ciprofloxacin in the Treatment of Acute Exacerbations of Chronic Bronchitis....Pages 97-102
Evaluation of Ciprofloxacin in the Treatment of Pseudomonas aeruginosa Infections....Pages 103-106
Use of Ciprofloxacin in the Treatment of Pseudomonas aeruginosa Infections....Pages 107-111
Ciprofloxacin in the Treatment of Acute Bacterial Diarrhea: A Double Blind Study....Pages 112-114
Treatment of Uncomplicated Gonococcal Urethritis in Men with Two Dosages of Ciprofloxacin....Pages 115-117
Ciprofloxacin in the Treatment of Urinary Tract Infection due to Enterobacteria....Pages 118-119
Ciprofloxacin in the Treatment of Infections Caused by Gentamicin-Resistant Gram-Negative Bacteria....Pages 119-122
Ciprofloxacin in the Treatment of Urinary Tract Infection in Patients with Multiple Sclerosis....Pages 122-124
Comparison of Intravenous Ciprofloxacin and Mezlocillin in Treatment of Complicated Urinary Tract Infection....Pages 124-126
Ciprofloxacin in the Treatment of Urinary Tract Infections Caused by Pseudomonas aeruginosa and Multiresistant Bacteria....Pages 126-128
Clinical Evaluation of Treatment with Ciprofloxacin....Pages 128-130
Treatment of Chronic Salmonella Carriers with Ciprofloxacin....Pages 131-132